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Pascal Meier1,2,3*, Franz H Messerli3, Andreas Baumbach4 and Alexandra J Lansky2Abstract
Hypertension is one of the most important and common cardiovascular risk factors. Defining the level at which blood
pressure starts causing end-organ damage is challenging, and is not easily answered. The threshold of blood pressure
defining hypertension has progressively been reduced over time, from systolic >160 mmHg to >150 mmHg, then
to >140 mmHg; and now even blood pressures above 130 to 120 mmHg are labeled as ‘pre-hypertension’ by some
expert committees. Are interest groups creating another ‘pseudodisease’ or is this trend scientifically justified?
A recent meta-analysis published in BMC Medicine by Huang et al. clearly indicates that pre-hypertension
(120 to 140/80 to 90 mmHg) is a significant marker of increased cardiovascular risk. This raises the question as to
whether we now need to lower the threshold of ‘hypertension’ (as opposed to ‘pre-hypertension’) to >120/80 mmHg,
redefining a significant proportion of currently healthy people as ‘patients’ with an established disease. These data
need to be interpreted with some caution. It is controversial whether pre-hypertension is an independent risk factor or
just a risk marker and even more controversial whether treatment of pre-hypertension will lower cardiovascular risk.
Please see related research: http://www.biomedcentral.com/1741-7015/11/177.
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The systematic review by Huang et al. addresses a very
important public health topic [1]. What exactly is hyper-
tension? The English clergyman Stephen Hales was the
first to describe and define ‘blood pressure’ circa 1730
when he measured the rise in a column of blood in a
glass tube bound into an artery. Measuring blood pressure
non-invasively was first performed in 1854 by the German
physician Karl Vierordt, and later in a simplified manner by
the Italian physician Scipione Riva-Rocci in 1896. Measur-
ing blood pressure is one of the oldest and remains the
most common medical examinations. Nevertheless, the
absolute blood pressure threshold to define hypertension
remains controversial, as we still do not fully understand
at what level high blood pressure becomes a ‘disease’ and
cardiovascular risk factor (Table 1).
As illustrated by these variable definitions from differ-
ent committees, it is difficult to come up with a clear
cut-off value to define ‘good’ and ‘bad’. While clinicians
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stated.there is a continuous association between blood pressure
and cardiovascular risk [2].
In a recent study published in BMC Medicine, Huang
et al. challenge current guidelines which label blood pres-
sures >140/>90 mmHg as being ‘normal’ by concluding
that pre-hypertension (even at lower levels of 120 to 129/80
to 84 mmHg) is a significant cardiovascular risk factor.New evidence
Huang et al. have performed a systematic review on the
clinical relevance of pre-hypertension [1]. They performed
a pooled analysis of 18 prospective cohort studies including
a total of 468,561 patients. Patients with pre-hypertension
had a 55% increased risk for cardiovascular disease, a
50% increased risk for coronary artery disease, and a
71% increased stroke risk (RR 1.71 (95% confidence interval
1.55 to 1.89)). The authors went a step further and
subdivided the pre-hypertension group into ‘low-range
pre-hypertension’ and ‘higher-range pre-hypertension’.
Even in the low-range pre-hypertension cohort, defined by
blood pressures of 120 to 129/80 to 84 mmHg, the risk of
cardiovascular disease was 46% higher than for individuals
with normal blood pressures (RR 1.46 (1.32 to 1.62)).
Therefore, according to this very large analysis, eventd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Table 1 Definitions and thresholds from various
professional bodies
Professional body Classifications Systolic
values
(mmHg)
Diastolic
values
(mmHg)
European Society of
Cardiology (ESC), 2013
Optimal <120 <80
Normal 120 to 129 80 to 84
High normal 130 to 139 85 to 89
Grade I hypertension 140 to 159 90 to 99
Grade II 160 to 179 100 to 109
Grade III >179 >109
Isolated systolic
hypertension
>139 <90
Joint National Committee
(JNC 7), 2003
Normal <120 <80
Pre-hypertension 120 to 139 80 to 89
Hypertension ≥140 ≥90
National Institute for
Health and Care
Excellence (NICE), 2011
Normal <140 <90
Stage I hypertension ≥140 ≥90
Stage II hypertension ≥160 ≥100
Severe hypertension ≥180 ≥110
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on morbidity and mortality.
Let us now have a closer look at some individual studies
included in this meta-analysis. The Framingham Heart
Study (6,859 participants who were initially free of
hypertension and cardiovascular disease) showed a 2.5-fold
increased risk for cardiovascular events at 10 years for
women and a 1.6-fold increase for men with blood pressures
between 130 to 139/85 to 89 mmHg [3]. In line with the
meta-analysis of Huang et al., the Framingham study further
showed an increased risk even for those with blood pressure
values of 120 to 129/80 to 84 mmHg compared with those
with ‘optimal’ blood pressure (<120/<80 mmHg). Another
very important study in this context is the Women's
Health Initiative, involving over 60,785 women in their
postmenopausal phase. Pre-hypertensive women showed
a 76% increased risk for cardiovascular death, a 93% in-
creased risk for myocardial infarction and 36% increased
risk for stroke [4]. One endpoint that was not assessed in
these studies was the impact of pre-hypertension on one
important end organ: the kidneys. One study that did assess
pre-hypertension and microalbuminuria as an early sign of
kidney dysfunction showed an increased incidence com-
pared to patients with optimal blood pressure [5]. This
finding further supports the findings of Huang et al.
The question arises based on these data, whether we
should now reclassify ‘pre-hypertension’ as ‘hypertension’,
even at the low blood pressure (BP) range, which wouldapply to a significant proportion of the population as newly
labeled hypertensive patients? It is estimated that about
37% of people in the US, that is, more than 100 million fall
within this pre-hypertension category. Whether these
patients would benefit from pharmacologic therapy and
if so, what the exact cost/benefit relation would be remains
uncertain. Pre-hypertension is clearly associated with
cardiovascular risk, but it is questionable whether a
blood pressure level in this pre-hypertension range is a
causal risk factor for cardiovascular events per se. We
know that pre-hypertensive individuals are much more
likely to progress to hypertension. In the Framingham
cohort, patients with ‘higher range pre-hypertension’
(130 to 139/85 to 89 mmHg) developed hypertension in
37% of cases, those with ‘lower range pre-hypertension’
developed hypertension in 18% of cases and those with
‘optimal blood pressure’ only in 5% of cases, over a 4-year
period in patients >65 years [3]. Of course, the long-term
cardiovascular event rate is higher in those people, and this
may not be related to their history of pre-hypertension. Be-
yond that, there are probably other ‘confounding factors’.
Even though most studies used multivariate adjustments to
reduce confounding bias, such adjustments can only be
made for available measured variables. It is likely that there
are other factors which were not measured and which inde-
pendently influence blood pressure and cardiovascular out-
comes, such as environmental and genetic factors.Therapeutic implications
The question still remains whether active treatment of
pre-hypertension will prevent progression to more ad-
vanced hypertension and future cardiovascular events.
Experimental data indicate that it may actually be possible
to change the natural history of pre-hypertension. In a
hypertensive rat model, if antihypertensive therapy is
given within the first 2 to 6 weeks of life it can prevent
the development of hypertension [6].
In the clinical setting, these findings could not be
fully confirmed. The ‘TRial of Preventing Hypertension’
(TROPHY) study was a 4-year trial of 806 patients with
pre-hypertension who were randomly assigned to 2 years
of therapy with either candesartan or placebo (16 mg/day)
[7]. After 2 years, all patients continued therapy with
placebo for another 2 years. At 2 years, the systolic and
diastolic pressures were significantly lower with candesartan
therapy compared to placebo. However, within 9 months
of cessation of candesartan therapy, the pressures rose to
values similar to those in the placebo group. Similarly,
in the Medical Research Council trial in nearly 3,000
participants using thiazide diuretic or beta blockers versus
placebo, the blood pressures dropped during therapy, but
within 6 months after cessation, reached the levels of the
placebo group [8].
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not seem to prevent progression to hypertension, the
question remains as to whether it reduces CV risk? Data
on this question are conflicting. A recent meta-analysis
pooling the results of trials of antihypertensive treatment in
patients with cardiovascular disease but without hyperten-
sion showed a benefit. It was based on 25 randomized trials
and 64,162 participants and found a 23% reduction in the
risk of stroke, a 20% reduced risk of myocardial infarction,
a 15% reduced risk of heart failure and a 13% reduced mor-
tality risk [9]. Whether this also applies to individuals with-
out manifest cardiovascular disease is unclear.Ambulatory blood pressure measurement (ABPM)
ABPM has become a useful tool to evaluate the true blood
pressure burden and it has been shown to be a better
predictor of cardiovascular events than are office blood
pressure measurements. In a recent study of almost 5,000
patients from the Spanish ABPM Registry 60% of patients
with office pressure of 130 to 139/85 to 89 mmHg, 42%
with office pressure of 140 to 159/90 to 99 mmHg and
53% with office blood pressures of above 160/100 mmHg
were actually normotensive according to the 24-h ABPM
measuring criteria, that is, their mean ABPM was below
130/80 mmHg) [10]. Clearly therefore office blood pres-
sure measurements can be deceptive in identifying the
specific stage of hypertensive cardiovascular disease. This
problem was also encountered in a very recent analysis of
Mahfoud et al., in patients who had renal denervation on
ABPM. There was a significant reduction of 8 to 10 mm
Hg systolic and 4 to 7 mm Hg diastolic, but clearly less
impressive that the reduction of the office blood pressure
in the same population (21 to 27 mm Hg (systolic)) and
(9 to 12 mm (diastolic)) [11].Conclusions
The data of Huang et al. clearly indicate that a blood
pressure level currently defined as pre-hypertension is a
significant marker of increased cardiovascular risk.
However, we lack evidence that pre-hypertensive blood
pressure itself is harmful and that an earlier intervention
to reduce the blood pressure is beneficial in the absence of
cardiovascular disease. Since pre-hypertensive individuals
are at a high risk to progress to sustained hypertension,
we advise periodic screening.
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